[1] |
Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence- What is it and what can it tell us?[J]. N Engl J Med,2016,375(23):2293-2297.
|
[2] |
Kaplan NM, Sproul LE, Mulcahy WS. Large prospective study of ramipril in patients with hypertension. CARE Investigators[J]. Clin Ther,1993,15(5):810-818.
|
[3] |
Food and Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices: draft guidance for industry and Food and Drug Administration staff[EB/OL].
URL
|
[4] |
Network for Excellence in Health Innovation. Real world evidence: a new era for health care innovation[EB/OL].
URL
|
[5] |
Alam I, Brown K, Donovan C, et al. Real-world effectiveness of simeprevir-containing regimens among patients with chronic hepatitis C virus: the SONET study[J]. Open Forum Infect Dis,2017,4(1):258.
|
[6] |
Robson C. Real world research 3rd Edn[M]. John Wiley & Sons Ltd, United Kingdom. 2011.
|
[7] |
梁远波, 吴越, 郑景伟. "真实世界"研究的产生背景,概念,方法及其在眼科的应用[J]. 中华眼视光学与视觉科学杂志,2013,15(12):756-759.
|
[8] |
Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study[J]. J Clin Oncol,2013,31(29):3647-3655.
|
[9] |
Xie W, Cao Y, Xu M, et al. Prognostic significance of elevated cholestatic enzymes for fibrosis and hepatocellular carcinoma in hospital discharged chronic viral hepatitis patients[J]. Sci Rep,2017,7(1):10289.
|
[10] |
Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering frugs: The CVD-REAL dtudy (vomparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors)[J]. Circulation, 2017,136(3):249-259.
|
[11] |
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med,2015,373(22):2117-2128.
|
[12] |
Bamberger M, Rugh J, Mabry L. Real world evaluation: working under budget, time, data, and political constraints[M]. Sage, 2011.
|
[13] |
席晓宇, 王欣, 陈磊. 医药卫生领域真实世界研究的主要问题及改进方法[J]. 卫生经济研究,2016,35(12):9-12.
|
[14] |
康德英. 浅议真实世界研究[J]. 中国癌症防治杂志,2017,9(2):100-103.
|
[15] |
王思成, 刘保延, 熊宁宁, 等. 真实世界临床研究伦理问题及策略探讨[J]. 中国中西医结合杂志,2013,33(4):437-442.
|
[16] |
国家食品药品监督管理总局药品审评中心. 临床试验数据管理工作技术指南[EB/OL]. 国食药监注[2016]112号.
URL
|
[17] |
国家食品药品监督管理总局药品审评中心. 药物临床试验伦理审查工作指导原则[EB/OL]. 国食药监注[2010]436号.
URL
|
[18] |
曾琳, 陶立元, 赵一鸣. 真实世界临床研究容易忽视的几点问题[J]. 中华儿科杂志,2015,53(10):746.
|
[19] |
李敏, 时景璞, 于慧会. 真实世界研究与随机对照试验,单病例随机对照试验在临床治疗性研究中的关系比较[J]. 中华流行病学杂志,2012,33(3):342-345.
|
[20] |
中华医学会肝病学分会中华医学会感染病学分会. 慢性乙型肝炎防治指南2010年更新版[J/CD]. 中华实验和临床感染病杂志:电子版,2011,5(1):50-60.
|
[21] |
慢性乙型肝炎特殊患者抗病毒治疗专家委员会. 慢性乙型肝炎特殊患者抗病毒治疗专家共识[J/CD]. 中国肝脏病杂志:电子版,2010,2(1):54-58.
|